LHFPL2

Across TCGA pan-cancer cohorts, LHFPL2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of LHFPL2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where LHFPL2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types LHFPL2 is over-expressed in tumor.

CCRCC, PDAC, and HNSC are the cancer types where LHFPL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LHFPL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	II,III,IV	+0.755	<.001	8	view →
PDAC	Male	All	+0.830	.011	4	view →
HNSC	All	All	+0.525	.002	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

LHFPL2–CCRCC

Open the CCRCC breakdown →